BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26456125)

  • 1. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.
    Modlin IM; Frilling A; Salem RR; Alaimo D; Drymousis P; Wasan HS; Callahan S; Faiz O; Weng L; Teixeira N; Bodei L; Drozdov I; Kidd M
    Surgery; 2016 Jan; 159(1):336-47. PubMed ID: 26456125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
    Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
    Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
    van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
    Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
    Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
    J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
    Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors.
    Partelli S; Andreasi V; Muffatti F; Schiavo Lena M; Falconi M
    Ann Surg Oncol; 2020 Oct; 27(10):3928-3936. PubMed ID: 32253675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
    Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
    Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy.
    Modlin IM; Kidd M; Frilling A; Falconi M; Filosso PL; Malczewska A; Kitz A
    Ann Surg; 2021 Sep; 274(3):481-490. PubMed ID: 34183517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
    Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
    Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
    Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity and Specificity of the NETest: A Validation Study.
    Al-Toubah T; Cives M; Valone T; Blue K; Strosberg J
    Neuroendocrinology; 2021; 111(6):580-585. PubMed ID: 32615553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression.
    Filosso PL; Kidd M; Roffinella M; Lewczuk A; Chung KM; Kolasinska-Cwikla A; Cwikla J; Lowczak A; Doboszynska A; Malczewska A; Catalano M; Zunino V; Boita M; Arvat E; Cristofori R; Guerrera F; Oliaro A; Tesselaar M; Buikhuisen W; Kos-Kudla B; Papotti M; Bodei L; Drozdov I; Modlin I
    Eur J Cardiothorac Surg; 2018 Mar; 53(3):631-639. PubMed ID: 29145657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.
    Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
    Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).
    Modlin IM; Kidd M; Oberg K; Falconi M; Filosso PL; Frilling A; Malczewska A; Salem R; Toumpanakis C; Laskaratos FM; Partelli S; Roffinella M; von Arx C; Kudla BK; Bodei L; Drozdov IA; Kitz A
    Ann Surg Oncol; 2021 Nov; 28(12):7506-7517. PubMed ID: 34008138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility.
    Modlin IM; Drozdov I; Kidd M
    Clin Chem Lab Med; 2014 Mar; 52(3):419-29. PubMed ID: 24127543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
    Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
    Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
    Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study.
    van Treijen MJC; Korse CM; van Leeuwaarde RS; Saveur LJ; Vriens MR; Verbeek WHM; Tesselaar MET; Valk GD
    Front Endocrinol (Lausanne); 2018; 9():740. PubMed ID: 30564197
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
    Liu E; Paulson S; Gulati A; Freudman J; Grosh W; Kafer S; Wickremesinghe PC; Salem RR; Bodei L
    Oncologist; 2019 Jun; 24(6):783-790. PubMed ID: 30158287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.